Open access · US-GOV via ClinicalTrials.gov Clinical trial

Longitudinal Study Comparing Markers of Frailty in Geriatric Assessment to Detect Vulnerability to Chemotherapy in Patients Aged 70 Years or Older With Colon Cancer

Authors not listed

Association Sud pour la Recherche en Oncogériatrie · 2010

Dysbiosis Human Randomized controlled trial

Abstract

MOST is a longitudinal study whose aim is to test the hypothesis that frailty markers are better at detecting vulnerable patients and that they are a better "Adverse Events" predictive tool than the CGA (Comprehensive Geriatric Assessment) in older cancer patients referred for chemotherapy. The second hypothesis is that a brief screening tool based on a combination of some frailty markers and some used in the CGA would help the oncologist detect patients requiring a more complete geriatric assessment

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-24 MST

Cite this

APA

Anonymous. (2010). Longitudinal Study Comparing Markers of Frailty in Geriatric Assessment to Detect Vulnerability to Chemotherapy in Patients Aged 70 Years or Older With Colon Cancer. <em>Association Sud pour la Recherche en Oncogériatrie</em>. https://clinicaltrials.gov/study/NCT02148731

Vancouver

Anonymous. Longitudinal Study Comparing Markers of Frailty in Geriatric Assessment to Detect Vulnerability to Chemotherapy in Patients Aged 70 Years or Older With Colon Cancer. Association Sud pour la Recherche en Oncogériatrie. 2010.

BibTeX

@misc{anon2010Longit, title = {Longitudinal Study Comparing Markers of Frailty in Geriatric Assessment to Detect Vulnerability to Chemotherapy in Patients Aged 70 Years or Older With Colon Cancer}, author = {Anonymous}, journal = {Association Sud pour la Recherche en Oncogériatrie}, year = {2010}, }